Published in final edited form as:

Tetrahedron Lett. 2010 March 31; 51(13): 1635–1638. doi:10.1016/j.tetlet.2009.12.091.

An efficient synthesis of the tamandarin B macrocycle

Kenneth M. Lassen, Jisun Lee, and Madeleine M. Joullie*

Department of Chemistry, University of Pennsylvania, 231 S. 34th Street, Philadelphia, PA 19104 USA

Abstract

A reliable, high yielding cyclization protocol for the macrocycle of tamandarin B is presented. This strategy will facilitate the synthesis of side chain analogues.

Keywords

Tamandarin B; Macrolactamization; Peptide coupling; Natural products

Introduction

Since their discovery by Rinehart and co-workers the didemnins¹ have been of great interest to the synthetic and medicinal chemistry communities. Didemnin B (**1**) was the first marine natural product to reach phase II clinical trials.² Didemnin B and other related analogs have stimulated many total syntheses to date.^{3–7} Tamandarins A (**2**) and B (**3**) were reported by Vervoort and Fenical in 2000 and found to possess a very similar structure to that of the didemnins.⁸ The main structural difference is that the didemnins possess a 23-membered ring containing a more complex $\alpha(\alpha$ -isovalerylpropionyl) (Hip) residue while the tamandarins possess a 21-membered ring containing a simpler hydroxyisovaleric (Hiv) acid residue. Macrolactamization at the Pro⁴-N,O-Me₂-Tyr⁵ junction has so far provided the highest yields for the didemnins^{6,9} and tamandarin macrocyclic analogs.^{10,11} A reliable, high yielding cyclization protocol for tamandarin B would make the macrocycle more available and facilitate the synthesis of side chain analogues.

Results

The retrosynthetic analysis (Scheme 1) shows the desired cyclization at the Pro⁴-N,O-Me₂-Tyr⁵ junction. In the previous synthesis, cyclization occurred at the Thr-Nst position.^{12,13} The new linear precursor (**5**) may be divided into three fragments; N,O-Me₂-Tyr-Thr (**6**), carboxylic acid (**7**), and Pro-Leu-Hiv (**8**) unit.

The synthesis commenced with the formation of the Pro-Leu-Hiv fragment **8** (Scheme 2). Proline benzyl ester (**9**) was coupled to Boc-Leu with diethyl cyanophosphonate (DEPC) to yield amide **10** in good yield.⁶ The Boc group was removed and the resulting salt was coupled

© 2009 Elsevier Ltd. All rights reserved

*Corresponding author. Tel.: +1 215 898 3158; fax: +1 215 573 9711. mjoullie@sas.upenn.edu (M.M. Joullie).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

to hydroxyisovaleric acid (**11**) using BOP (Benzotriazol-1-yloxy)tris(dimethylamino) phosphonium hexafluorophosphate) to yield the desired alcohol **8**.

The norstatine fragment was synthesized next (Scheme 3). Boc-D-Valine (**12**) was activated as its pentafluorophenyl ester (**14**) and condensed with the lithium enolate of methyl acetate to yield β -ketoester **15**. The ketone was reduced using potassium borohydride to provide alcohol **16**. The resulting alcohol was protected as its TBS ether and the methyl ester was hydrolyzed to yield desired acid **7**.¹⁰

The last fragment to be synthesized was the *N,O*-Me₂-Tyr-Thr fragment **6** (Scheme 4). Tyrosine derivative **18** was made by known procedures.⁴ A carbodiimide mediated esterification with alcohol **19** resulted in the desired product (**20**). Removal of the methyl ester with trimethyltin hydroxide resulted in acid **6** in excellent yield.¹⁴

The reaction of acid **7** and alcohol **8** with EDCI (*N*-(3-Dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride), DCC (dicyclohexyl carbodiimide), or isopropenyl chloroformate did not result in a high yield of **21** (Scheme 5). As in the first generation synthesis, lactam formation from the activated acid was the major product (**22**) of these reactions.¹³

In order to decrease the nucleophilicity of the carbamate nitrogen, oxazolidine **23** was synthesized from alcohol **16** (Scheme 6). Methyl ester **23** was then hydrolyzed to acid **24** which was then subjected to the reaction conditions.

Oxazolidine acid **24** successfully prevented lactam formation and provided the desired product **25** in 94% yield (Scheme 7). This change in protecting group prevented the undesired side reaction and improved the overall yield significantly. After removal of the Boc group and oxazolidine fragmentation under acidic conditions, the resulting salt was coupled to acid **6** to form the protected linear precursor **5**. The terminal protecting groups were then removed under hydrogenolysis conditions to afford the linear precursor. Cyclization with PyAOP ((7-Azabenzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate) led to the desired macrocycle (**4**) in good yield.

Conclusion

The tamandarin B macrocycle has been made using a second generation strategy by cyclization at the Pro⁴-*N,O*-Me₂-Tyr⁵ junction. This macrocycle synthesis is highly convergent and provides useful quantities for analog synthesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank NIH (CA-40081) for financial support. Financial support for the departmental instrumentation was provided by the National Institutes of Health (1S10RR23444-1). We also thank Dr. George Furst and Dr. Rakesh Kohli for NMR and MS assistance, respectively.

References

- (1). Rinehart KL Jr, Gloer JB, Cook JC Jr, Mizesak SA, Scabill TA. J. Am. Chem. Soc 1981;103:1857–1859.
- (2). Vera MD, Joullie MM. Med. Res. Rev 2002;22:102–145. [PubMed: 11857636]

- (3). Rinehart KL Jr, Kishore V, Nagarajan S, Lake RJ, Gloer JB, Bozich FA, Li KM, Maleczka RE Jr, Todsens WL, Munro MHG, Sullins DW, Sakai R. J. Am. Chem. Soc 1987;109:6846–6848.
- (4). Li W-R, Ewing WR, Harris BD, Joullié MM. J. Am. Chem. Soc 1990;112:7659–7672.
- (5). Jouin P, Poncet J, Dufour M-N, Pantaloni A, Castro B. J. Org. Chem 1989;54:617–627.
- (6). Hamada Y, Kondo Y, Shibata M, Shioiri T. J. Am. Chem. Soc 1989;111:669–673.
- (7). Schmidt U, Kroner M, Griesser H. Tetrahedron Lett 1988;29:3057–3060. 4407–4408.
- (8). Vervoort H, Fenical W, de A. Epifanio R. J. Org. Chem 2000;65:782–792. [PubMed: 10814011]
- (9). Jou G, Gonzales I, Albericio F, Lloyd-Williams P, Giralt E. J. Org. Chem 1997;62:354–366. [PubMed: 11671410]
- (10). Adrio J, Cuevas C, Manzanares I, Joullié MM. Org. Lett 2006;8:511–514. [PubMed: 16435872]
- (11). Adrio J, Cuevas C, Manzanares I, Joullié MM. J. Org. Chem 2007;72:5129–5138. [PubMed: 17555353]
- (12). Joullié MM, Portonovo P, Liang B, Richard DJ. Tetrahedron Lett 2000;41:9373–9376.
- (13). Liang B, Richard DJ, Portonovo P, Joullié MM. J. Am. Chem. Soc 2001;123:4469–4474. [PubMed: 11457232]
- (14). Nicolaou KC, Estrada AA, Zak M, Lee SH, Safina BS. Angew. Chem. Int. Ed 2005;44:1378–1382.
- (15). *Selected data. Compound 4.* **¹H NMR** (500 MHz, CDCl₃) δ 0.80–1.03 (m, 18H), 1.25 (d, *J*= 6.45 Hz, 3H), 1.43 (s, 9H), 1.53–1.71 (m, 4H), 1.73–1.80 (m, 4H), 1.96–2.21 (m, 4H), 2.46 (dd, *J*=16.96, 6.72 Hz, 1H), 2.56 (s, 3H), 2.85–2.94 (m, 1H), 3.14 (dd, *J*= 14.44, 10.89 Hz, 1H), 3.36 (dd, *J*= 14.22, 4.32 Hz, 1H), 3.55 (dd, *J*= 10.47, 4.47 Hz, 1H), 3.64 (d, *J*= 6.00 Hz, 2H), 3.70 (t, *J*= 9.29 Hz, 1H), 3.77 (s, 3H), 3.98 (t, *J*= 6.16 Hz, 1H), 4.32 (dd, *J*= 10.37, 3.12 Hz, 1H), 4.58 (dd, *J*= 7.85, 4.60 Hz, 1H), 4.88 (t, *J*= 9.92 Hz, 1H), 4.95 (m, 2H), 5.00 (dd, *J*= 6.30, 3.20 Hz, 1H), 6.82 (d, *J*= 8.44 Hz, 2H), 7.06 (d, *J*= 8.44 Hz, 2H), 7.53 (d, *J*= 9.64 Hz, 1H), 7.95 (d, *J*= 8.49 Hz, 1H); **¹³C NMR** (125 MHz, CDCl₃) δ 15.1, 18.0, 18.5, 20.2, 20.7, 23.5, 24.9, 27.6, 28.0, 30.4, 34.0, 38.5, 38.9, 46.7, 48.3, 55.2, 55.8, 57.1, 60.3, 65.8, 68.9, 71.4, 79.2, 80.2, 114.1, 129.9, 130.3, 155.8, 158.6, 168.6, 169.7, 170.4, 171.3, 171.6, 172.8; **HRMS** (ESI) *m/z* calculated for C₄₃H₆₈N₅O₁₂ (M + H)⁺: 846.4864, found: 846.4869; **IR** (cm⁻¹): 3341, 2961, 2873, 1741, 1669, 1636, 1514, 1166; [α]_D^{18.7} –90.1 (c 0.7, CH₂Cl₂).

Figure 1.
Structures of didemnin B (**1**) and tamandarins A (**2**) and B (**3**).

Scheme 1.
Retrosynthetic analysis

Scheme 2.
Synthesis of alcohol **8**

Scheme 3.
Synthesis of acid **7**

Scheme 4.
Synthesis of acid **6**

Scheme 5.
Failed reaction conditions

Scheme 6.
Synthesis of oxazolidine acid **24**.

Scheme 7.
Linear precursor formation and cyclization